Celcuity Inc.

Businessfiled

Celcuity Inc. operates in Biotechnology, based in MINNEAPOLIS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Celcuity Inc. has raised $303M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $130M on 2021-04-08.

Most recent recorded round closed around 2023-10-20.

Filings read as a recurring offering program rather than a clean venture-stage ladder — interpret stage labels and step-ups with that in mind.

Valuation (modeled)modeled

Provath models Celcuity Inc. at approximately $692M (range $227M–$1.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.34× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 4 months.

Last raise 2.7 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 98% of Biotechnology peers (4293 compared).

Modeled value ranks above 86% of those peers.

Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.

Peoplefiled

10 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.

Recurring-offering pattern: stage-based valuation has lower applicability.